ESR1 and triple-negative breast carcinoma: We first treated MCF7 (estrogen receptor-positive, ER+) and MDA-MB-231 (MB231) (triple-negative breast cancer, TNBC) cells with five types of LCFAs—LA, OA, elaidic acid (EA, C18:1, trans), PA, and α-linolenic acid (LNA, C18:3, ω-3)—at various concentrations.